Switzerland· 67444001
Poteligeo 4 mg/ml, Konzentrat zur Herstellung einer Infusionslösung
A mogamulizumab product containing mogamulizumabum, registered in Switzerland by Kyowa Kirin Sàrl and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Mogamulizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX09 (mogamulizumab), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Mogamulizumab · ATC L01FX09
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of mogamulizumab costs, country by country.
Normalised to the WHO defined daily dose (5 mg), so markets compare like for like.
- Switzerland: $432.02 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Mogamulizumab · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$432.02
The record
At a glance
Swissmedic (Switzerland)- Active substance
- mogamulizumabum
- Manufacturer
- Kyowa Kirin Sàrl
- Country
- Switzerland (CH)
- ATC code
- L01FX09
- ATC class
- Mogamulizumab
- Defined daily dose
- 5 mg, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680674440017Durchstf 1 StkCHF 1433.15
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
74 interactions on record for mogamulizumab.
Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Mogamulizumab · interactions on record
74 records
- 29 severe
- 38 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Mogamulizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainPOTELIGEO 4 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONKyowa Kirin Holdings B.V.
- FinlandPoteligeoOrifarm Oy
- CanadaPOTELIGEOKYOWA KIRIN, INC.
- CzechiaPOTELIGEOKyowa Kirin Holdings B.V., Hoofddorp
- FrancePOTELIGEO 4 mg/mL, solution à diluer pour perfusionKYOWA KIRIN HOLDINGS (PAYS-BAS)
- United KingdomPoteligeo 20mg/5ml concentrate for solution for infusion vialsKyowa Kirin Ltd
- IrelandPOTELIGEO 4 mg/mL concentrate for solution for infusionKyowa Kirin Holdings B.V.
- IcelandPoteligeoKyowa Kirin Holdings B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Poteligeo
- Liechtenstein · Poteligeo
- Norway · Poteligeo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4a70566d-e144-409f-b84b-0b931502a155 GET /v1/drugs/4a70566d-e144-409f-b84b-0b931502a155?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "mogamulizumabum 20 mg",
"valid_from": "2026-03-01",
"limitations": "[{\"description\":\"Poteligeo wird vergütet für die systemische Monotherapie von erwachsenen Patientinnen und Patienten mit histologisch bestätigter Diagnose einer rezidivierter oder refraktärer Mycosis fungoides (MF) oder Sézary-Syndrome (SS)<br>\\n• ohne large cell transformation (LCT)<br>\\n• ohne viszerale Beteiligung<br>\\ndie mindestens eine vorherige Therapie mit Methotrexat erhalten haben und unzureichend auf diese angesprochen, oder diese nicht vertragen.<br>\\nAusschliesslich für Patienten ohne allogene hämatopoetische Stammzelltransplantation in der Vorgeschichte.<br>\\nDie Behandlung mit Mogamulizumab wird bis zur Progression der Erkrankung oder einer inakzep-tablen Toxizität vergütet. Wenn nach 4 Monaten Behandlung kein Ansprechen auf Kompartiment-ebene ohne Verbesserung der Lebensqualität oder eine Gesamtprogression beobachtet wird, wird die Behandlung nicht weiter vergütet.<br>\\n<br>\\nDie Zulassungsinhaberin erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für jede bezogene Packung POTELIGEO einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\n<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21341.01<br> \\n<br>\",\"costApproval\":null,\"indication\":\"21341.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-03-01\",\"validTo\":\"2029-02-28\"}]",
"galenic_form": "Inf Konz 4 mg/ml",
"therapeutic_area": null,
"sl_inclusion_date": "2023-01-01",
"self_retention_pct": 10
}See everything about mogamulizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.